VEGF and colon cancer growth beyond angiogenesis: Does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism?

Current Pharmaceutical Design

Volumn 20, Issue 7, 2014, Pages 1041-1044

  Ahluwalia, Amrita ^a   Jones, Michael K ^a   Matysiak Budnik, Tamara ^b   Tarnawski, Andrzej S ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Angiogenesis; Cancer cell growth; Colon cancer; VEGF

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

BIOSYNTHESIS; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PATHOPHYSIOLOGY; VASCULARIZATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84895095447     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819999131218175905     Document Type: Review

References (45)

1. Jones MK, Itani RM, Wang H, et al. Activation of VEGF and Ras genes in gastric mucosa during angiogenic response to ethanol injury. Am J Physiol 1999; 276: (6 Pt 1), G1345-55.
2. Jones MK, Kawanaka H, Baatar D, et al. Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. Gastroenterology 2001; 121: (5), 1040-7.
3. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: (18), 3964-8.
4. Kondo Y, Arii S, Mori A, Furutani M, Chiba T, Imamura M. Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin Cancer Res 2000; 6: (2), 622-30.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: (23), 2335-42.
6. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: (6423), 841-4.
7. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93: (25), 14765-70.
8. Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double blind, randomized phase III study (HORIZON III). J Clin Oncol 2012; 30: (29), 3588-95.
9. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: (4587), 983-5.
10. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: (2), 851-8.
11. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: (4935), 1306-9.
12. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in hu man hepatocellular carcinoma. Hepatology 1998; 28: (1), 68-77.
13. Shi B, Wang X, Yang Z. Vascular endothelial growth factors and liver diseases. Hepatogastroenterology 2001; 48: (40), 1145-8.
14. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: (6573), 439-42.
15. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: (6573), 435-9.
16. Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 50 Suppl 1: S24-S33.
17. Tolstanova G, Khomenko T, Deng X, et al. Neutralizing antivascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther 2009; 328: (3), 749-57.
18. Tolstanova G, Khomenko T, Deng X, Szabo S, Sandor Z. New molecular mechanisms of the unexpectedly complex role of VEGF in ulcerative colitis. Biochem Biophys Res Commun 2010; 399: (4), 613-6.
19. Afuwape AO, Kiriakidis S, Paleolog EM. The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol 2002; 17: (3), 961-72.
20. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: (7), 1258-65.
21. Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000; 60: (11), 2898-905.
22. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: (2), 139-47.
23. Duncan TJ, Al Attar A, Rolland P, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 2008; 14: (10), 3030-5.
24. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77: (5), 858-63.
25. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: (21), 1182-6.
26. Yin Y, Cao LY, Wu WQ, Li H, Jiang Y, Zhang HF. Blocking effects of siRNA on VEGF expression in human colorectal cancer cells. World J Gastroenterol 2010; 16: (9), 1086-92.
27. Tai J, Wang G, Liu T, Wang L, Lin C, Li F. Effects of siRNA Targeting c-Myc and VEGF on Human Colorectal Cancer Volo Cells. J Biochem Mol Toxicol 2012; 26: (12), 499-505.
28. Zhang YM, Dai BL, Zheng L, et al. A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation. Cell Death Dis 2012; 3: e406.
29. Hong SW, Jung KH, Choi MJ, et al. Anticancer effects of KI-10F: a novel compound affecting apoptosis, angiogenesis and cell growth in colon cancer. Int J Oncol 2012; 41: (5), 1715-22.
30. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005; 24: (16), 2647-53.
31. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: (4), 1789-97.
32. Smith NR, Baker D, James NH, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010; 16: (14), 3548-61.
33. Harada Y, Ogata Y, Shirouzu K. Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer. Int J Clin Oncol 2001; 6: (5), 221-8.
34. Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 2008; 68: (1), 285-91.
35. Coron E, Mosnier JF, Ahluwalia A, et al. Colonic mucosal biopsies obtained during confocal endomicroscopy are pre-stained with fluorescein in vivo and are suitable for histologic evaluation. Endoscopy 2012; 44: (2), 148-53.
36. Ahluwalia A, Jones MK, Szabo S, et al. Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism. Biochem Biophys Res Commun 2013; 437: (4), 515-20.
37. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 1996; 271: (46), 29483-8.
38. Yonezawa M, Wada K, Tatsuguchi A, et al. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer. Digestion 2009; 80: (4), 215-25.
39. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 69 Suppl 3: 11-6.
40. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: (4), 581-611.
41. Ahluwalia A, Tarnawski AS. Critical role of hypoxia sensor-HIF-1alpha in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem 2012; 19: (1), 90-7.
42. Lucarini G, Zizzi A, Belvederesi L, Kyriakidou K, Mazzucchelli R, Biagini G. Increased VEGF165 expression in HCT116 colon cancer cells after transient transfection with a GFP vector encoding HIF-1 gene. J Exp Clin Cancer Res 2007; 26: (4), 515-9.
43. Gentile LB, Piva B, Diaz BL. Hypertonic stress induces VEGF production in human colon cancer cell line Caco-2: inhibitory role of autocrine PGE(2). PLoS One 2011; 6: (9), e25193.
44. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003; 63: (9), 2330-4.
45. Calviello G, Di Nicuolo F, Gragnoli S et al. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and-2 and HIF-1alpha induction pathway. Carcinogenesis 2004; 25: (12), 2303-10.